Gene × Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models

Neural Plasticity

Volumn 2016, Issue , 2016, Pages

  Moran, Paula ^a   Stokes, Jennifer ^b   Marr, Julia ^b   Bock, Gavin ^b   Desbonnet, Lieve ^c   Waddington, John ^d,e   O'Tuathaigh, Colm ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^e SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DYSBINDIN; NEU DIFFERENTIATION FACTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; REELIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ADOLESCENCE; ANIMAL MODEL; CANNABIS USE; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNE FUNCTION TEST; INFECTION; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; MOUSE; MOUSE MUTANT; NONHUMAN; REVIEW; RISK FACTOR; RODENT MODEL; SCHIZOPHRENIA; SOCIAL STRESS; ANIMAL; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS;

ANIMALS; DISEASE MODELS, ANIMAL; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84990935792     PISSN: 20905904     EISSN: 16875443     Source Type: Journal    
DOI: 10.1155/2016/2173748     Document Type: Review

References (207)

1. A. S. Brown, "Prenatal infection as a risk factor for schizophrenia, " Schizophrenia Bulletin, vol. 32, no. 2, pp. 200-202, 2006.
2. A. S. Brown, "The environment and susceptibility to schizophrenia, " Progress in Neurobiology, vol. 93, no. 1, pp. 23-58, 2011.
3. P. D. Harvey, A. P. Wingo, K. E. Burdick, and R. J. Baldessarini, "Cognition and disability in bipolar disorder: lessons from schizophrenia research, " Bipolar Disorders, vol. 12, no. 4, pp. 364-375, 2010.
4. J. L. Waddington, R. J. Hennessy, C. M. P. O'Tuathaigh et al., "Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redux, " in The Origins of Schizophrenia, A. S. Brown and P. H. Patterson, Eds., pp. 3-21, Columbia University Press, New York, NY, USA, 2012.
5. M. J. Owen, A. Sawa, and P. B. Mortensen, "Schizophrenia, " The Lancet, vol. 388, no. 10039, pp. 86-97, 2016.
6. A. Gustavsson, M. Svensson, F. Jacobi et al., "Cost of disorders of the brain in Europe 2010, " European Neuropsychopharmacology, vol. 21, no. 10, pp. 718-779, 2011.
7. H. U. Wittchen, F. Jacobi, J. Rehm et al., "The size and burden of mental disorders and other disorders of the brain in Europe 2010, " European Neuropsychopharmacology, vol. 21, no. 9, pp. 655-679, 2011.
8. S. Leucht and S. Heres, "Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia, " Journal of Clinical Psychiatry, vol. 67, no. 5, pp. 3-8, 2006.
9. P. J. Harrison, "Recent genetic findings in schizophrenia and their therapeutic relevance, " Journal of Psychopharmacology, vol. 29, no. 2, pp. 85-96, 2015.
10. J. L. Rapoport, J. N. Giedd, and N. Gogtay, "Neurodevelopmental model of schizophrenia: update 2012, " Molecular Psychiatry, vol. 17, no. 12, pp. 1228-1238, 2012.
11. J. Gratten, N. R. Wray, M. C. Keller, and P. M. Visscher, "Largescale genomics unveils the genetic architecture of psychiatric disorders, " Nature Neuroscience, vol. 17, no. 6, pp. 782-790, 2014.
12. M. Burmeister, "Basic concepts in the study of diseases with complex genetics, " Biological Psychiatry, vol. 45, no. 5, pp. 522-532, 1999.
13. M. Burmeister, M. G. McInnis, and S. Zöllner, "Psychiatric genetics: progress amid controversy, " Nature Reviews Genetics, vol. 9, no. 7, pp. 527-540, 2008.
14. S. Zammit, M. J. Owen, and G. Lewis, "Misconceptions about gene-environment interactions in psychiatry, " Evidence-Based Mental Health, vol. 13, no. 3, pp. 65-68, 2010.
15. M. R. Munafò, S. Zammit, and J. Flint, "Practitioner Review: A critical perspective on gene-environment interaction models-what impact should they have on clinical perceptions and practice" Journal of Child Psychology and Psychiatry and Allied Disciplines, vol. 55, no. 10, pp. 1092-1101, 2014.
16. R. A. Shih, P. L. Belmonte, and P. P. Zandi, "A review of the evidence from family, twin and adoption studies for a geneticcontribution to adult psychiatric disorders, " International Review of Psychiatry, vol. 16, no. 4, pp. 260-283, 2004.
17. C. A. Prescott and I. I. Gottesman, "Genetically mediated vulnerability to schizophrenia, " Psychiatric Clinics of North America, vol. 16, no. 2, pp. 245-267, 1993.
18. M. S. Keshavan, "Development, disease and degeneration in schizophrenia: A unitary pathophysiological model, " Journal of Psychiatric Research, vol. 33, no. 6, pp. 513-521, 1999.
19. S. Tosato, P. Dazzan, and D. Collier, "Association between the neuregulin 1 gene and schizophrenia: A systematic review, " Schizophrenia Bulletin, vol. 31, no. 3, pp. 613-617, 2005.
20. M. J. Owen, "Implications of genetic findings for understanding schizophrenia, " Schizophrenia Bulletin, vol. 38, no. 5, pp. 904-907, 2012.
21. C. A. Ross, R. L. Margolis, S. A. J. Reading, M. Pletnikov, and J. T. Coyle, "Neurobiology of schizophrenia, " Neuron, vol. 52, no. 1, pp. 139-153, 2006.
22. M. C. O'Donovan, N. J. Craddock, and M. J. Owen, "Genetics of psychosis; insights from views across the genome, " Human Genetics, vol. 126, no. 1, pp. 3-12, 2009.
23. D. S. Rudd, M. Axelsen, E. A. Epping, N. C. Andreasen, and T. H. Wassink, "A genome-wide CNV analysis of schizophrenia reveals a potential role for a multiple-hit model, " American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 165, no. 8, pp. 619-626, 2014.
24. T. Karl, "Neuregulin 1: A prime candidate for research into gene-environment interactions in schizophrenia Insights from genetic rodent models, " Frontiers in Behavioral Neuroscience, vol. 7, article 106, 2013.
25. G. Kannan, A. Sawa, and M. V. Pletnikov, "Mouse models of gene-environment interactions in schizophrenia, " Neurobiology of Disease, vol. 57, pp. 5-11, 2013.
26. C. M. O'Tuathaigh and J. L. Waddington, "Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness, " Neuroscience and Biobehavioral Reviews, vol. 58, pp. 19-35, 2015.
27. V. Labrie, S. Pai, and A. Petronis, "Epigenetics of major psychosis: progress, problems and perspectives, " Trends in Genetics, vol. 28, no. 9, pp. 427-435, 2012.
28. Y. Ayhan, R. McFarland, andM. V. Pletnikov, "Animalmodels of gene-environment interaction in schizophrenia: A dimensional perspective, " Progress in Neurobiology, vol. 136, pp. 1-27, 2016.
29. D. Malaspina, "Paternal factors and schizophrenia risk: de novo mutations and imprinting, " Schizophrenia Bulletin, vol. 27, no. 3, pp. 379-393, 2001.
30. A. Reichenberg, R. Gross, S. Sandin, and E. S. Susser, "Advancing paternal and maternal age are both important for autism risk, " American Journal of Public Health, vol. 100, no. 5, pp. 772-773, 2010.
31. A. Kong, M. L. Frigge, G. Masson et al., "Rate of de novo mutations and the importance of father's age to disease risk, " Nature, vol. 488, no. 7412, pp. 471-475, 2012.
32. M. C. Perrin, A. S. Brown, and D. Malaspina, "Aberrant epigenetic regulation could explain the relationship of paternal age to schizophrenia, " Schizophrenia Bulletin, vol. 33, no. 6, pp. 1270-1273, 2007.
33. R. G. Smith, A. Reichenberg, R. L. Kember et al., "Advanced paternal age is associated with altered DNA methylation at brain-expressed imprinted loci in inbred mice: implications for neuropsychiatric disease, " Molecular Psychiatry, vol. 18, no. 6, pp. 635-636, 2013.
34. P. F. Sullivan, K. S. Kendler, and M. C. Neale, "Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies, " Archives of General Psychiatry, vol. 60, no. 12, pp. 1187-1192, 2003.
35. International Schizophrenia Consortium, "Rare chromosomal deletions and duplications increase risk of schizophrenia, " Nature, vol. 455, pp. 237-241, 2008.
36. H. Stefansson, D. Rujescu, S. Cichon et al., "Large recurrent microdeletions associated with schizophrenia, " Nature, vol. 455, pp. 232-236, 2008.
37. G. Kirov, D. Rujescu, A. Ingason, D. A. Collier, M. C. O'Donovan, and M. J. Owen, "Neurexin 1 (NRXN1) deletions in schizophrenia, " Schizophrenia Bulletin, vol. 35, no. 5, pp. 851-854, 2009.
38. P. V. Gejman, A. R. Sanders, and K. S. Kendler, "Genetics of schizophrenia: new findings and challenges, " Annual Review of Genomics and Human Genetics, vol. 12, pp. 121-144, 2011.
39. Schizophrenia Working Group of the Psychiatric Genomics Consortium, "Biological insights from 108 schizophreniaassociated genetic loci, " Nature, vol. 511, pp. 421-427, 2014.
40. C. L. Winchester, J. A. Pratt, and B. J. Morris, "Risk genes for schizophrenia: Translational opportunities for drug discovery, " Pharmacology andTherapeutics, vol. 143, no. 1, pp. 34-50, 2014.
41. S. M. Purcell, J. L. Moran, M. Fromer et al., "A polygenic burden of rare disruptivemutations in schizophrenia, " Nature, vol. 506, no. 7487, pp. 185-190, 2014.
42. J. Hall, S. Trent, K. L. Thomas, M. C. O'Donovan, and M. J. Owen, "Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity, " Biological Psychiatry, vol. 77, no. 1, pp. 52-58, 2015.
43. Cross-Disorder Group of the Psychiatric Genomics Consortium, "Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs, " Nature Genetics, vol. 45, pp. 984-994, 2013.
44. D. M. Ruderfer, A. H. Fanous, S. Ripke et al., "Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia, " Molecular Psychiatry, vol. 19, no. 9, pp. 1017-1024, 2014.
45. S. A. McCarroll, G. Feng, and S. E. Hyman, "Genome-scale neurogenetics: methodology and meaning, " Nature Neuroscience, vol. 17, no. 6, pp. 756-763, 2014.
46. F. Cirulli, N. Francia, A. Berry, L. Aloe, E. Alleva, and S. J. Suomi, "Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates, " Neuroscience and Biobehavioral Reviews, vol. 33, no. 4, pp. 573-585, 2009.
47. E. J. Nestler and S. E. Hyman, "Animal models of neuropsychiatric disorders, " Nature Neuroscience, vol. 13, no. 10, pp. 1161-1169, 2010.
48. J. van Os, G. Kenis, and B. P. F. Rutten, "The environment and schizophrenia, " Nature, vol. 468, no. 7321, pp. 203-212, 2010.
49. L. Gray and A. J. Hannan, "Dissecting cause and effect in the pathogenesis of psychiatric disorders: genes, environment and behaviour, " Current Molecular Medicine, vol. 7, no. 5, pp. 470-478, 2007.
50. B. Abazyan, J. Nomura, G. Kannan et al., "Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology, " Biological Psychiatry, vol. 68, no. 12, pp. 1172-1181, 2010.
51. M. Niwa, R. S. Lee, T. Tanaka, K. Okada, S. Kano, and A. Sawa, "Acritical period of vulnerability to adolescent stress: epigeneticmediators in mesocortical dopaminergic neurons, " Human Molecular Genetics, vol. 25, no. 7, pp. 1370-1381, 2016.
52. T. D. Cannon, T. G. M. Van Erp, C. E. Bearden et al., "Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions, " Schizophrenia Bulletin, vol. 29, no. 4, pp. 653-669, 2003.
53. C. M. O'Tuathaigh, L. Desbonnet, P. M. Moran, and J. L. Waddington, "Susceptibility genes for schizophrenia: mutant models, endophenotypes and psychobiology, " Current Topics in Behavioural Neuroscience, vol. 12, pp. 209-250, 2012.
54. D. Braff, N. J. Schork, and I. I. Gottesman, "Endophenotyping schizophrenia, " American Journal of Psychiatry, vol. 164, no. 5, pp. 705-707, 2007.
55. B. N. Cuthbert andT. R. Insel, "Toward the future of psychiatric diagnosis: The seven pillars of RDoC, " BMC Medicine, vol. 11, article 126, 2013.
56. B. D. Kelly, E. O'Callaghan, J. L. Waddington et al., "Schizophrenia and the city: A review of literature and prospective study of psychosis and urbanicity in Ireland, " Schizophrenia Research, vol. 116, no. 1, pp. 75-89, 2010.
57. P. Casadio, C. Fernandes, R. M. Murray, and M. Di Forti, "Cannabis use in young people: The risk for schizophrenia, " Neuroscience and Biobehavioral Reviews, vol. 35, no. 8, pp. 1779-1787, 2011.
58. J. J. McGrath, M. R. Pemberton, J. L. Welham, and R. M. Murray, "Schizophrenia and the influenza epidemics of 1954, 1957 and 1959: A southern hemisphere study, " Schizophrenia Research, vol. 14, no. 1, pp. 1-8, 1994.
59. M. Cannon, D. Cotter, V. P. Coffey et al., "Prenatal exposure to the 1957 influenza epidemic and adult schizophrenia: A followup study, " British Journal of Psychiatry, vol. 168, pp. 368-371, 1996.
60. P. B. Mortensen, C. B. Pedersen, T. Westergaard et al., "Effects of family history and place and season of birth on the risk of schizophrenia, "The New England Journal of Medicine, vol. 340, no. 8, pp. 603-608, 1999.
61. S. L. Buka, T. D. Cannon, E. F. Torrey, andR. H. Yolken, "Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring, " Biological Psychiatry, vol. 63, no. 8, pp. 809-815, 2008.
62. A. S. Brown and E. J. Derkits, "Prenatal infection and schizophrenia: A review of epidemiologic and translational studies, " The American Journal of Psychiatry, vol. 167, no. 3, pp. 261-280, 2010.
63. U. Meyer, J. Feldon, M. Schedlowski, and B. K. Yee, "Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia, "Neuroscience and Biobehavioral Reviews, vol. 29, no. 6, pp. 913-947, 2005.
64. U. Meyer, J. Feldon, M. Schedlowski, and B. K. Yee, "Immunological stress at the maternal-foetal interface: A link between neurodevelopment and adult psychopathology, " Brain, Behavior, and Immunity, vol. 20, no. 4, pp. 378-388, 2006.
65. U. Meyer, P. J. Murray, A. Urwyler, B. K. Yee, M. Schedlowski, and J. Feldon, "Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling, " Molecular Psychiatry, vol. 13, no. 2, pp. 208-221, 2008.
66. B. K. Bitanihirwe, D. Peleg-Raibstein, F. Mouttet, J. Feldon, and U. Meyer, "Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia, " Neuropsychopharmacology, vol. 35, no. 12, pp. 2462-2478, 2010.
67. L. Shi, S. H. Fatemi, R. W. Sidwell, and P. H. Patterson, "Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring, "The Journal of Neuroscience, vol. 23, no. 1, pp. 297-302, 2003.
68. U. Meyer, M. Nyffeler, A. Engler et al., "The time of prenatal immune challenge determines the specificity of inflammationmediated brain and behavioral pathology, " The Journal of Neuroscience, vol. 26, no. 18, pp. 4752-4762, 2006.
69. L. Zuckerman, M. Rehavi, R. Nachman, and I. Weiner, "Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: A novel neurodevelopmental model of schizophrenia, " Neuropsychopharmacology, vol. 28, no. 10, pp. 1778-1789, 2003.
70. S. E. P. Smith, J. Li, K. Garbett, K. Mirnics, and P. H. Patterson, "Maternal immune activation alters fetal brain development through interleukin-6, " The Journal of Neuroscience, vol. 27, no. 40, pp. 10695-10702, 2007.
71. N. V. Malkova, C. Z. Yu, E. Y. Hsiao, M. J. Moore, and P. H. Patterson, "Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism, " Brain, Behavior, and Immunity, vol. 26, no. 4, pp. 607-616, 2012.
72. L. Zuckerman and I. Weiner, "Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation, " Psychopharmacology, vol. 169, no. 3-4, pp. 308-313, 2003.
73. K. Zavitsanou, C. K. Lim, T. Purves-Tyson et al., "Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration byCOX-2 inhibition, " Brain, Behavior, and Immunity, vol. 41, no. 1, pp. 173-181, 2014.
74. Y. Piontkewitz, M. Arad, and I. Weiner, "Abnormal trajectories of neurodevelopment and behavior following in utero insult in the rat, " Biological Psychiatry, vol. 70, no. 9, pp. 842-851, 2011.
75. S. Reisinger, D. Khan, E. Kong, A. Berger, A. Pollak, and D. D. Pollak, "The Poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery, " Pharmacology andTherapeutics, vol. 149, pp. 213-226, 2015.
76. H. Stefansson, E. Sigurdsson, V. Steinthorsdottir et al., "Neuregulin 1 and susceptibility to schizophrenia, " American Journal of Human Genetics, vol. 71, no. 4, pp. 877-892, 2002.
77. Y. G. Gong, C. N. Wu, Q. H. Xing, X. Z. Zhao, J. Zhu, and L. He, "A two-method meta-analysis of Neuregulin 1(NRG1) association and heterogeneity in schizophrenia, " Schizophrenia Research, vol. 111, no. 1-3, pp. 109-114, 2009.
78. H. C. Loh, P. Y. Tang, S. F. Tee et al., "Neuregulin-1 (NRG-1) and its susceptibility to schizophrenia: A case-control study and meta-analysis, " Psychiatry Research, vol. 208, no. 2, pp. 186-188, 2013.
79. P. J. Harrison and A. J. Law, "Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology, " Biological Psychiatry, vol. 60, no. 2, pp. 132-140, 2006.
80. L. Mei andW.-C. Xiong, "Neuregulin 1 in neural development, synaptic plasticity and schizophrenia, " Nature Reviews Neuroscience, vol. 9, no. 6, pp. 437-452, 2008.
81. K. Hänninen, H. Katila, M. Saarela et al., "Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia, " European Archives of Psychiatry and Clinical Neuroscience, vol. 258, no. 1, pp. 10-15, 2007.
82. K. Marballi, M. P. Quinones, F. Jimenez et al., "In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation, " Journal of Molecular Medicine, vol. 88, no. 11, pp. 1133-1141, 2010.
83. T. Kato, A. Kasai, M. Mizuno et al., "Phenotypic characterization of transgenic mice overexpressing neuregulin-1, " PLoS ONE, vol. 5, no. 12, Article IDe14185, 2010.
84. T. Karl, L. Duffy, A. Scimone, R. P. Harvey, and P. R. Schofield, "Alteredmotor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia, " Genes, Brain and Behavior, vol. 6, no. 7, pp. 677-687, 2007.
85. C. M. P. O'Tuathaigh, D. Babovic, G. J. O'Sullivan et al., "Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1, " Neuroscience, vol. 147, no. 1, pp. 18-27, 2007.
86. L. Desbonnet, C. O'Tuathaigh, G. Clarke et al., "Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: A putative model of gene ™ environment interaction, " Brain, Behavior, and Immunity, vol. 26, no. 4, pp. 660-671, 2012.
87. M. van den Buuse, L. Wischhof, R. X. Lee, S. Martin, and T. Karl, "Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic druginduced hyperlocomotion and prepulse inhibition regulation, " International Journal of Neuropsychopharmacology, vol. 12, no. 10, pp. 1383-1393, 2009.
88. T. Karl, T. H. J. Burne, M. Van den Buuse, and R. Chesworth, "Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit" Behavioural Brain Research, vol. 223, no. 2, pp. 336-341, 2011.
89. M. Rimer, D. W. Barrett, M. A. Maldonado, V. M. Vock, and F. Gonzalez-Lima, "Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition, " NeuroReport, vol. 16, no. 3, pp. 271-275, 2005.
90. Y.-J. J. Chen, M. A. Johnson, M. D. Lieberman et al., "Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components, " The Journal of Neuroscience, vol. 28, no. 27, pp. 6872-6883, 2008.
91. J.-C. Pei, C.-M. Liu, and W.-S. Lai, "Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophreniarelated cognitive deficits, " Frontiers in Behavioral Neuroscience, vol. 8, article 126, 2014.
92. C. O'Leary, L. Desbonnet, N. Clarke et al., "Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1, " Neuroscience, vol. 277, pp. 294-305, 2014.
93. D. H. R. Blackwood, A. Fordyce, M. T. Walker, D. M. St. Clair, D. J. Porteous, and W. J. Muir, "Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family, " American Journal ofHuman Genetics, vol. 69, no. 2, pp. 428-433, 2001.
94. N. A. Sachs, A. Sawa, S. E. Holmes, C. A. Ross, L. E. DeLisi, and R. L. Margolis, "A frameshift mutation in disrupted in schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder, "Molecular Psychiatry, vol. 10, no. 8, pp. 758-764, 2005.
95. N. J. Bradshaw and D. J. Porteous, "DISC1-binding proteins in neural development, signalling and schizophrenia, " Neuropharmacology, vol. 62, no. 3, pp. 1230-1241, 2012.
96. N. J. Brandon and A. Sawa, "Linking neurodevelopmental and synaptic theories of mental illness through DISC1, " Nature Reviews Neuroscience, vol. 12, no. 12, pp. 707-722, 2011.
97. S. J. Clapcote, T. V. Lipina, J. K. Millar et al., "Behavioral phenotypes of Disc1 missense mutations in mice, " Neuron, vol. 54, no. 3, pp. 387-402, 2007.
98. T. Hikida, H. Jaaro-Peled, S. Seshadri et al., "Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected bymeasures translatable to humans, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 36, pp. 14501-14506, 2007.
99. W. Li, Y. Zhou, J. D. Jentsch et al., "Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 46, pp. 18280-18285, 2007.
100. M. Kvajo, H. McKellar, P. A. Arguello et al., "A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 19, pp. 7076-7081, 2008.
101. M. V. Pletnikov, Y. Ayhan, O. Nikolskaia et al., "Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia, " Molecular Psychiatry, vol. 13, no. 2, pp. 173-186, 2008.
102. S. Shen, B. Lang, C. Nakamoto et al., "Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated DISC1, " The Journal of Neuroscience, vol. 28, no. 43, pp. 10893-10904, 2008.
103. Y. Mao, X. Ge, C. L. Frank et al., "Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3/-catenin signaling, " Cell, vol. 136, no. 6, pp. 1017-1031, 2009.
104. T. V. Lipina, C. Zai, D. Hlousek, J. C. Roder, and A. H. C. Wong, "Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice, " The Journal of Neuroscience, vol. 33, no. 18, pp. 7654-7666, 2013.
105. D. Ibi, T. Nagai, Y. Kitahara et al., "NeonatalpolyI:Ctreatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood, " Neuroscience Research, vol. 64, no. 3, pp. 297-305, 2009.
106. T. Nagai, Y. Kitahara, D. Ibi, T. Nabeshima, A. Sawa, and K. Yamada, "Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal polyI:C treatment, " Behavioural Brain Research, vol. 225, no. 1, pp. 305-310, 2011.
107. B. Abazyan, J. Dziedzic, K. Hua et al., "Chronic exposure of mutantDISC1 mice to lead produces sex-dependent abnormalities consistent with schizophrenia and related mental disorders: A gene-environment interaction study, " Schizophrenia Bulletin, vol. 40, no. 3, pp. 575-584, 2014.
108. B. Kadkhodaei, T. Ito, E. Joodmardi et al., "Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons, " The Journal of Neuroscience, vol. 29, no. 50, pp. 15923-15932, 2009.
109. P. Rojas, E. Joodmardi, Y. Hong, T. Perlmann, and S. O. ögren, "Adult mice with reduced Nurr1 expression: An animal modelfor schizophrenia, " Molecular Psychiatry, vol. 12, no. 8, pp. 756-766, 2007.
110. S. Vuillermot, E. Joodmardi, T. Perlmann, S. O. ögren, J. Feldon, and U. Meyer, "Prenatal immune activation interacts with genetic Nurr1 deficiency in the development of attentional impairments, " The Journal of Neuroscience, vol. 32, no. 2, pp. 436-451, 2012.
111. B. Hibell, U. Guttormsson, S. Ahlström et al., The 2011 ESPAD Report. Substance Use Among Students in 36 European Countries, The Swedish Council for Information on Alcohol and Other Drugs (CAN), Stockholm, Sweden, 2012.
112. L. D. Johnston, P. M. O'Malley, J. G. Bachman et al., Monitoring the Future National Survey Results on Drug Use, 1975-2013: Volume I, Secondary School Students, Institute for Social Research, The University of Michigan, Ann Arbor, Mich, USA, 2014.
113. D. Linszen and T. van Amelsvoort, "Cannabis and psychosis: An update on course and biological plausiblemechanisms, " Current Opinion in Psychiatry, vol. 20, no. 2, pp. 116-120, 2007.
114. T. H. Moore, S. Zammit, A. Lingford-Hughes et al., "Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review, " The Lancet, vol. 370, no. 9584, pp. 319-328, 2007.
115. D. M. Fergusson, L. J. Horwood, and N. R. Swain-Campbell, "Cannabis dependence and psychotic symptoms in young people, " Psychological Medicine, vol. 33, no. 1, pp. 15-21, 2003.
116. L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi, and T. E. Moffitt, "Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study, " BritishMedical Journal, vol. 325, no. 7374, pp. 1212-1213, 2002.
117. L. Arseneault, M. Cannon, J. Witton, and R. M. Murray, "Causal association between cannabis and psychosis: examination of the evidence, " British Journal of Psychiatry, vol. 184, pp. 110-117, 2004.
118. J. McGrath, J. Welham, J. Scott et al., "Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults, " Archives of General Psychiatry, vol. 67, no. 5, pp. 440-447, 2010.
119. J. Decoster, J. van Os, I. Myin-Germeys, M. De Hert, and R. van Winkel, "Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directions, " Current Pharmaceutical Design, vol. 18, no. 32, pp. 5015-5023, 2012.
120. R. Van Winkel, G. Esquivel, G. Kenis et al., "Genome-wide findings in schizophrenia and the role of gene-environment interplay, " CNS Neuroscience and Therapeutics, vol. 16, no. 5, pp. e185-e192, 2010.
121. L. French, C. Gray, G. Leonard et al., "Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence, " JAMA Psychiatry, vol. 72, no. 10, pp. 1002-1011, 2015.
122. D. Goldman, "America's cannabis experiment, " JAMA Psychiatry, vol. 72, no. 10, pp. 969-970, 2015.
123. C. M. P. O'Tuathaigh, M. Hryniewiecka, A. Behan et al., "Chronic adolescent exposure to-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes, " Neuropsychopharmacology, vol. 35, no. 11, pp. 2262-2273, 2010.
124. M. Schneider and M. Koch, "Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognitionmemory, and theperformance inaprogressive ratio task in adult rats, " Neuropsychopharmacology, vol. 28, no. 10, pp. 1760-1769, 2003.
125. J. Renard, L. G. Rosen, M. Loureiro et al., "Adolescent cannabinoid exposure induces a persistent sub-cortical hyper-dopaminergic state and associated molecular adaptations in the prefrontal cortex, " Cerebral Cortex, 2016.
126. P. D. Morrison and R. M. Murray, "From real-world events to psychosis: The emerging neuropharmacology of delusions, " Schizophrenia Bulletin, vol. 35, no. 4, pp. 668-674, 2009.
127. S. Han, B.-Z. Yang, H. R. Kranzler et al., "Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans, " Biological Psychiatry, vol. 72, no. 8, pp. 637-644, 2012.
128. A. A. Boucher, G. E. Hunt, T. Karl, J. Micheau, I. S. McGregor, and J. C. Arnold, "Heterozygous neuregulin 1 mice display greater baseline and 9-tetrahydrocannabinol-induced c-Fos expression, " Neuroscience, vol. 149, no. 4, pp. 861-870, 2007.
129. A. A. Boucher, J. C. Arnold, L. Duffy, P. R. Schofield, J. Micheau, and T. Karl, "Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of 9-tetrahydrocannabinol, " Psychopharmacology, vol. 192, no. 3, pp. 325-336, 2007.
130. L. E. Long, R. Chesworth, J. C. Arnold, and T. Karl, "A followup study: Acute behavioural effects of 9-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice, " Psychopharmacology, vol. 211, no. 3, pp. 277-289, 2010.
131. A. A. Boucher, G. E. Hunt, J. Micheau et al., "The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids, " International Journal of Neuropsychopharmacology, vol. 14, no. 5, pp. 631-643, 2011.
132. L. E. Long, R. Chesworth, X.-F. Huang, I. S. McGregor, J. C. Arnold, and T. Karl, "Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeatedTHCexposure in adolescence, " International Journal of Neuropsychopharmacology, vol. 16, no. 1, pp. 163-175, 2013.
133. J. R. Spencer, K. M. E. Darbyshire, A. A. Boucher et al., "Novelmolecular changes induced by Nrg1 hypomorphismand Nrg1-cannabinoid interaction in adolescence: A hippocampal proteomic study in mice, " Frontiers in CellularNeuroscience, vol. 7, article 15, 2013.
134. J. A. S. Crippa, G. N. Derenusson, T. B. Ferrari et al., "Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report, " Journal of Psychopharmacology, vol. 25, no. 1, pp. 121-130, 2011.
135. F. M. Leweke, J. K. Mueller, B. Lange et al., "Therapeutic potential of cannabinoids in psychosis, " Biological Psychiatry, vol. 79, no. 7, pp. 604-612, 2015.
136. L. E. Long, R. Chesworth, X.-F. Huang et al., "Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice, " PLoS ONE, vol. 7, no. 4, Article ID e34129, 2012.
137. M. D. Ballinger, A. Saito, B. Abazyan et al., "Adolescent cannabis exposure interacts with mutant DISC1 to produce impaired adult emotional memory, " Neurobiology of Disease, vol. 82, pp. 176-184, 2015.
138. E. M. Tunbridge, D. R. Weinberger, and P. J. Harrison, "A novel protein isoform of catechol O-methyltransferase (COMT): brain expression analysis in schizophrenia and bipolar disorder and effect of Val158Met genotype, " Molecular Psychiatry, vol. 11, no. 2, pp. 116-117, 2006.
139. D. Collip, R. Van Winkel, O. Peerbooms et al., "COMT Val158Met-stress interaction in psychosis: role of background psychosis risk, " CNS Neuroscience and Therapeutics, vol. 17, no. 6, pp. 612-619, 2011.
140. X. Goldberg, M. Fatjó-Vilas, S. Alemany, I. Nenadic, C. Gastó, and L. Fañanás, "Gene-environment interaction on cognition: A twin study of childhood maltreatment and COMT variability, " Journal of Psychiatric Research, vol. 47, no. 7, pp. 989-994, 2013.
141. S. Alemany, B. Arias, M. Fatjó-Vilas et al., "Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes, " Acta Psychiatrica Scandinavica, vol. 129, no. 1, pp. 54-62, 2014.
142. A. Caspi, T. E. Moffitt, M. Cannon et al., "Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction, " Biological Psychiatry, vol. 57, no. 10, pp. 1117-1127, 2005.
143. C. M. P. O'Tuathaigh, G. Clarke, J. Walsh et al., "Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes, " International Journal ofNeuropsychopharmacology, vol. 15, no. 9, pp. 1331-1342, 2012.
144. á. T. Behan, M. Hryniewiecka, C. M. P. O'Tuathaigh et al., "Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways, " Neuropsychopharmacology, vol. 37, no. 7, pp. 1773-1783, 2012.
145. L. J. Phillips, P. D. McGorry, B. Garner et al., "Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders, " Australian and New Zealand Journal of Psychiatry, vol. 40, no. 9, pp. 725-741, 2006.
146. K. D. Tessner, V. Mittal, and E. F. Walker, "Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders, " Schizophrenia Bulletin, vol. 37, no. 2, pp. 432-441, 2011.
147. F. Varese, E. Barkus, and R. P. Bentall, "Dissociation mediates the relationship between childhood trauma and hallucinationproneness, " PsychologicalMedicine, vol. 42, no. 5, pp. 1025-1036, 2012.
148. J.-P. Selten and E. Cantor-Graae, "Hypothesis: social defeat is a risk factor for schizophrenia" The British Journal of Psychiatry, vol. 191, no. 51, pp. s9-s12, 2007.
149. J.-P. Selten, E. van der Ven, B. P. F. Rutten, and E. Cantor-Graae, "The social defeat hypothesis of schizophrenia: An update, " Schizophrenia Bulletin, vol. 39, no. 6, pp. 1180-1186, 2013.
150. C. Hammels, E. Pishva, J. De Vry et al., "Defeat stress in rodents: from behavior to molecules, " Neuroscience and Biobehavioral Reviews, vol. 59, pp. 111-140, 2015.
151. O. Berton, C. A. McClung, R. J. DiLeone et al., "Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress, " Science, vol. 311, no. 5762, pp. 864-868, 2006.
152. V. Krishnan, M. Han, D. L. Graham et al., "Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions, " Cell, vol. 131, no. 2, pp. 391-404, 2007.
153. T. W. Chohan, A. A. Boucher, J. R. Spencer et al., "Partial genetic deletion of neuregulin 1 modulates the effects of stress on sensorimotor gating, dendritic morphology, and HPA axis activity in adolescent mice, " Schizophrenia Bulletin, vol. 40, no. 6, pp. 1272-1284, 2014.
154. F. N. Haque, T. V. Lipina, J. C. Roder, and A. H. C. Wong, "Social defeat interacts with Disc1 mutations in the mouse to affect behavior, " Behavioural Brain Research, vol. 233, no. 2, pp. 337-344, 2012.
155. M. Niwa, H. Jaaro-Peled, S. Tankou et al., "Adolescent stressinduced epigenetic control of dopaminergic neurons via glucocorticoids, " Science, vol. 339, no. 6117, pp. 335-339, 2013.
156. R. E. Straub, Y. Jiang, C. J. MacLean et al., "Genetic variation in the 6p22. 3 Gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia, " American Journal of Human Genetics, vol. 71, no. 2, pp. 337-348, 2002.
157. B. Riley, P.-H. Kuo, B. S. Maher et al., "The dystrobrevin binding protein 1 (DTNBP1) gene is associated with schizophrenia in the Irish Case Control Study of Schizophrenia (ICCSS) sample, " Schizophrenia Research, vol. 115, no. 2-3, pp. 245-253, 2009.
158. M. Ayalew, H. Le-Niculescu, D. F. Levey et al., "Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction, "Molecular Psychiatry, vol. 17, no. 9, pp. 887-905, 2012.
159. K. E. Burdick, T. E. Goldberg, B. Funke et al., "DTNBP1 genotype influences cognitive decline in schizophrenia, " Schizophrenia Research, vol. 89, no. 1-3, pp. 169-172, 2007.
160. A. J. Fallgatter, A.-C. Ehlis, M. J. Herrmann et al., "DTNBP1 (dysbindin) gene variantsmodulate prefrontal brain function in schizophrenic patients-support for the glutamate hypothesis of schizophrenias, " Genes, Brain and Behavior, vol. 9, no. 5, pp. 489-497, 2010.
161. J.-P. Zhang, K. E. Burdick, T. Lencz, and A. K. Malhotra, "Metaanalysis of genetic variation in DTNBP1 and general cognitive ability, " Biological Psychiatry, vol. 68, no. 12, pp. 1126-1133, 2010.
162. C. S. Weickert, D. A. Rothmond, T. M. Hyde, J. E. Kleinman, and R. E. Straub, "Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients, " Schizophrenia Research, vol. 98, no. 1-3, pp. 105-110, 2008.
163. J. Tang, R. P. LeGros, N. Louneva et al., "Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression, " HumanMolecular Genetics, vol. 18, no. 20, pp. 3851-3863, 2009.
164. C. Fu, D. Chen, R. Chen, Q. Hu, G. Wang, and K.-L. Lim, "The schizophrenia-related protein dysbindin-1A is degraded and facilitates NF-Kappa B activity in the nucleus, " PLoS ONE, vol. 10, no. 7, Article ID e0132639, 2015.
165. R. T. Swank, H. O. Sweet, M. T. Davisson, M. Reddington, and E. K. Novak, "Sandy: A new mouse model for platelet storage pool deficiency, " Genetical Research, vol. 58, no. 1, pp. 51-62, 1991.
166. K. Takao, K. Toyama, K. Nakanishi et al., "Impaired longterm memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia, " Molecular brain, vol. 1, article 11, 2008.
167. J. D. Jentsch, H. Trantham-Davidson, C. Jairl, M. Tinsley, T. D. Cannon, and A. Lavin, "Dysbindin modulates prefrontal cortical glutamatergic circuits andworkingmemory function in mice, " Neuropsychopharmacology, vol. 34, no. 12, pp. 2601-2608, 2009.
168. K. H. Karlsgodt, K. Robleto, H. Trantham-Davidson et al., "Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance, " Biological Psychiatry, vol. 69, no. 1, pp. 28-34, 2011.
169. F. Papaleo, F. Yang, S. Garcia et al., "Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways, "Molecular Psychiatry, vol. 17, no. 1, pp. 85-98, 2012.
170. W. B. Glen Jr., B. Horowitz, G. C. Carlson et al., "Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity andcontextual fear conditioning, " Hippocampus, vol. 24, no. 2, pp. 204-213, 2014.
171. S. K. Bhardwaj, R. T. Ryan, T. P. Wong, and L. K. Srivastava, "Loss of dysbindin-1, a risk gene for schizophrenia, leads to impaired group 1 metabotropic glutamate receptor function in mice, " Frontiers in Behavioral Neuroscience, vol. 9, article 72, 2015.
172. F. Papaleo and D. R. Weinberger, "Dysbindin and Schizophrenia: it's dopamine and glutamate all over again, " Biological Psychiatry, vol. 69, no. 1, pp. 2-4, 2011.
173. M. M. Cox, A. M. Tucker, J. Tang et al., "Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background, " Genes, Brain and Behavior, vol. 8, no. 4, pp. 390-397, 2009.
174. K. K. Nicodemus, S. Marenco, A. J. Batten et al., "Serious obstetric complications interact with hypoxia-regulated/vascularexpression genes to influence schizophrenia risk, " Molecular Psychiatry, vol. 13, no. 9, pp. 873-877, 2008.
175. J. Voisey, C. D. Swagell, I. P. Hughes et al., "A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia, " Behavioral and Brain Functions, vol. 6, article 41, 2010.
176. S. Hattori, T. Murotani, S. Matsuzaki et al., "Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia, " Biochemical and Biophysical Research Communications, vol. 373, no. 2, pp. 298-302, 2008.
177. C. A. Ghiani, M. Starcevic, I. A. Rodriguez-Fernandez et al., "The dysbindin-containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins and role in neurite outgrowth, " Molecular Psychiatry, vol. 15, no. 2, pp. 204-215, 2010.
178. T. C. Südhof and J. E. Rothman, "Membrane fusion: grappling with SNARE and SM proteins, " Science, vol. 323, no. 5913, pp. 474-477, 2009.
179. C. M. Lewis, D. F. Levinson, L. H. Wise et al., "Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia, " American Journal of Human Genetics, vol. 73, no. 1, pp. 34-48, 2003.
180. J. Lochman, V. J. Balcar, F. St'astný, and O. Sery, "Preliminary evidence for association between schizophrenia and polymorphisms in the regulatory regions of the ADRA2A, DRD3 and SNAP-25 genes, " Psychiatry Research, vol. 205, no. 1-2, pp. 7-12, 2013.
181. X. Fan and E. J. Hess, "D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD, " Neurobiology of Disease, vol. 26, no. 1, pp. 201-211, 2007.
182. X. Fan, M. Xu, and E. J. Hess, "D2 dopamine receptor subtypemediated hyperactivity and amphetamine responses in amodel of ADHD, " Neurobiology of Disease, vol. 37, no. 1, pp. 228-236, 2010.
183. P. L. Oliver and K. E. Davies, "Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk, " Human Molecular Genetics, vol. 18, no. 23, pp. 4576-4589, 2009.
184. M. Baca, A. M. Allan, L. D. Partridge, and M. C. Wilson, "Gene-environment interactions affect long-term depression (LTD) through changes in dopamine receptor affinity in Snap25 deficient mice, " Brain Research, vol. 1532, pp. 85-98, 2013.
185. T. Niitsu, T. Ishima, T. Yoshida et al., "A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia, " Psychiatry Research, vol. 215, no. 2, pp. 268-273, 2014.
186. C. Theleritis, H. L. Fisher, I. Shäfer et al., "Brain derived neurotropic factor (BDNF) is associated with childhood abuse but not cognitive domains in first episode psychosis, " Schizophrenia Research, vol. 159, no. 1, pp. 56-61, 2014.
187. E. Dong, P. Tueting, F. Matrisciano, D. R. Grayson, and A. Guidotti, "Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs, " Translational Psychiatry, vol. 6, article e711, 2016.
188. E. E. Manning, A. L. Halberstadt, and M. van den Buuse, "BDNF-deficient mice show reduced psychosis-related behaviors following chronic methamphetamine, " International Journal of Neuropsychopharmacology, vol. 19, no. 4, 2016.
189. E. E. Manning and M. van den Buuse, "BDNF deficiency and young-adult methamphetamine induce sex-specific effects on prepulse inhibition regulation, " Frontiers in Cellular Neuroscience, vol. 7, article 92, 2013.
190. S. H. Fatemi, J. A. Earle, and T. McMenomy, "Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression, " Molecular Psychiatry, vol. 5, no. 6, pp. 654-663, 2000.
191. I. Knuesel, "Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases, " Progress in Neurobiology, vol. 91, no. 4, pp. 257-274, 2010.
192. G. Laviola, E. Ognibene, E. Romano, W. Adriani, and F. Keller, "Gene-environment interaction during early development in the heterozygous reeler mouse: clues for modelling of major neurobehavioral syndromes, " Neuroscience and Biobehavioral Reviews, vol. 33, no. 4, pp. 560-572, 2009.
193. E. Ognibene, W. Adriani, S. Macr, and G. Laviola, "Neurobehavioural disorders in the infant reeler mouse model: interaction of genetic vulnerability and consequences of maternal separation, " Behavioural Brain Research, vol. 177, no. 1, pp. 142-149, 2007.
194. K. R. Howell and A. Pillai, "Effects of prenatal hypoxia on schizophrenia-related phenotypes in heterozygous reeler mice: A gene ™ environment interaction study, " European Neuropsychopharmacology, vol. 24, no. 8, pp. 1324-1336, 2014.
195. Y. Ayhan, A. Sawa, C. A. Ross, and M. V. Pletnikov, "Animal models of gene-environment interactions in schizophrenia, " Behavioural Brain Research, vol. 204, no. 2, pp. 274-281, 2009.
196. E. L. Burrows, C. E. McOmish, and A. J. Hannan, "Geneenvironment interactions and construct validity in preclinical models of psychiatric disorders, " Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 6, pp. 1376-1382, 2011.
197. I. Myin-Germeys, P. Delespaul, and J. van Os, "Behavioural sensitization to daily life stress in psychosis, " Psychological Medicine, vol. 35, no. 5, pp. 733-741, 2005.
198. R. D. Goodwin, X. F. Amador, D. Malaspina, S. A. Yale, R. R. Goetz, and J. M. Gorman, "Anxiety and substance use comorbidity among inpatients with schizophrenia, " Schizophrenia Research, vol. 61, no. 1, pp. 89-95, 2003.
199. I. Myin-Germeys, M. Oorschot, D. Collip, J. Lataster, p. delespaul, and J. van Os, "Experience sampling research in psychopathology: opening the black box of daily life, " Psychological Medicine, vol. 39, no. 9, pp. 1533-1547, 2009.
200. J. M. Goldstein, L. J. Seidman, J. M. Goodman et al., "Are there sex differences in neuropsychological functions among patientswith schizophrenia" American Journal of Psychiatry, vol. 155, no. 10, pp. 1358-1364, 1998.
201. M. Han, X.-F. Huang, D. C. Chen et al., "Gender differences in cognitive function of patients with chronic schizophrenia, " Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 39, no. 2, pp. 358-363, 2012.
202. D. A. Lewis, A. A. Curley, J. R. Glausier, and D. W. Volk, "Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia, " Trends in Neurosciences, vol. 35, no. 1, pp. 57-67, 2012.
203. S. Canetta, S. Bolkan, N. Padilla-Coreano et al., "Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons, "Molecular Psychiatry, vol. 21, no. 7, pp. 956-968, 2016.
204. J. vanOs and S. Kapur, "Schizophrenia, " The Lancet, vol. 374, no. 9690, pp. 635-645, 2009.
205. R. M. Murray, L. Sideli, C. La Cascia, andD. La Barbera, "Bridging the gap between research into biological and psychosocial models of psychosis, " Shanghai Archives of Psychiatry, vol. 27, no. 3, pp. 139-143, 2015.
206. O. D. Howes, C. McDonald, M. Cannon, L. Arseneault, J. Boydell, and R. M. Murray, "Pathways to schizophrenia: The impact of environmental factors, " International Journal of Neuropsychopharmacology, vol. 7, no. 1, pp. S7-S13, 2004.
207. P. J. Harrison and D. R. Weinberger, "Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence, " Molecular Psychiatry, vol. 10, no. 1, pp. 40-68, 2005.